BioLife Solutions, Inc. reported past fourth-quarter 2025 sales of US$24.76 million versus US$20.72 million a year earlier, with full-year 2025 revenue of US$96.21 million and a reduced net loss of ...

Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions, Inc. Q4 2025 ...

BioLife Solutions Inc (BLFS) reports a 29% annual revenue increase and outlines strategic initiatives for continued growth in 2026.

Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations ...

Q4 2025 earnings call recap: 2026 revenue guidance, margin outlook, CGT demand drivers, and QKine partnership.

Analysts expect the company to post a loss of $0.01 per share on revenue of $24.05 million for the quarter. That would mark a sharp sequential step back from the third quarter, when BioLife earned ...

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2025 fourth quarter ...

Lake Street analyst Thomas Flaten maintained a Buy rating on BioLife Solutions today and set a price target of $33.00. Flaten covers the Healthcare sector, focusing on stocks such as Aytu BioScience, ...

With headquarters in Cambridge, England, Qkine Limited is dedicated to advancing stem cell and regenerative medicine research by developing high-purity, bioactive growth factors and cytokines. With a ...

Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million ...